Propanc Biopharma, Inc.(PPCB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
PPCB Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Propanc Biopharma, Inc. (PPCB), a Healthcare sector company. PPCB is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q3 2026), Propanc Biopharma, Inc. reports net income of $-6.4M, free cash flow of $-1.1M. Top institutional holders of PPCB by reported 13-F value include UBS Group AG, JANE STREET GROUP,, Marex Group plc, based on the most recent SEC filings. PPCB trades on the Nasdaq exchange and files with the SEC under CIK 1517681. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PPCB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Propanc Biopharma, Inc. directly from SEC EDGAR.
Net Income
Q3 2026
$-6.4M
Free Cash Flow
Q3 2026
$-1.1M
ROIC
Q3 2026
-64.8%
D/E Ratio
Q3 2026
0.01
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-2114.7% YoYOperating Income
-3123.9% YoYEPS (Diluted)
-725.0% YoYTotal Assets
+32441.8% YoYTotal Debt
+37.7% YoYOp. Cash Flow
+63.3% YoY| Metric | FY 2025 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Net Income | $-58.9M -2114.7% | $-2.7M -0.1% | $-2.7M +43.9% | $-4.7M +17.7% | $-5.8M +18.2% | $-7.0M |
| Operating Income | $-57.3M -3123.9% | $-1.8M +10.8% | $-2.0M +43.0% | $-3.5M -33.6% | $-2.6M +34.0% | $-4.0M |
| EPS (Diluted) | $-14.85 -725.0% | $-1.80 +96.3% | $-49.23 | — | — | — |
| Total Assets | $19.6M +32441.8% | $60.3K -26.1% | $81.7K -17.1% | $98.5K -3.1% | $101.7K +42.4% | $71.4K |
| Total Debt | $537.9K +37.7% | $390.5K -57.8% | $926.4K -40.5% | $1.6M -6.0% | $1.7M -64.7% | $4.7M |
| Operating Cash Flow | $-405.2K +63.3% | $-1.1M +23.0% | $-1.4M +22.3% | $-1.8M +10.2% | $-2.1M +5.4% | $-2.2M |
AI Insight: PPCB Financial Trends
Pre-revenue biotech with massive Q1 2025 charge now burning $3–6M quarterly; equity eroding toward insolvency.
• Net loss spiked to $54M in Q1 2025, then normalized to $3–6M run rate through Q1 2026.
• Operating cash flow consistently negative or near-zero; Q3 2025 and Q1 2026 each burned $1–2M.
• Equity fell from $18M (Q1 2025) to $10M (Q1 2026); total debt minimal but cash runway tightening.
⚠ Q1 2025 $54M charge suggests one-time write-down or impairment; underlying burn rate $3–6M/quarter demands funding clarity.
⚠ Zero revenue and no material revenue inflection visible across all eight quarters; clinical or commercial milestone timing critical.
AI Insight: PPCB Ratio Trends
Pre-revenue biotech with severe profitability losses; minimal leverage but no operational metrics to assess progress.
• ROE deteriorated from -117.1% (Q2 2025) to -186.8% (TTM 2026), indicating widening net losses relative to equity base.
• Debt-to-equity ratio stable near 0.01–0.04 across all periods; company maintains minimal financial leverage.
⚠ No operating margin, NPM, or ROIC data reported; company lacks revenue/profitability to generate traditional efficiency metrics.
⚠ ROA ranged -83.0% to -81.8% in profitable quarters; asset base generating large losses with no visible inflection toward breakeven.
Get alerted when PPCB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Propanc Biopharma, Inc. including:
Top Institutional Holders of PPCB
UBS Group AG
$19.4K182,614 shJANE STREET GROUP, LLC
$15.2K143,212 shMarex Group plc
$7.2K67,724 shSassicaia Capital Advisers LLC
$1.7K16,000 shXTX Topco Ltd
$1.3K12,098 shVirtu Financial LLC
$4.0040,748 sh
| Fund | Value | Shares |
|---|---|---|
| UBS Group AG | $19.4K | 182,614 |
| JANE STREET GROUP, LLC | $15.2K | 143,212 |
| Marex Group plc | $7.2K | 67,724 |
| Sassicaia Capital Advisers LLC | $1.7K | 16,000 |
| XTX Topco Ltd | $1.3K | 12,098 |
| Virtu Financial LLC | $4.00 | 40,748 |
More Healthcare Companies
View all Healthcare →Put PPCB on your watchlist
Track score changes the day Propanc Biopharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PPCB a good stock to buy?
13F Pro's AI-powered analysis of Propanc Biopharma, Inc. (PPCB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PPCB are available on the PPCB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own PPCB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PPCB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Propanc Biopharma, Inc.'s investment landscape.